7dzx › Citations

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
<div class='caption-title'>Effect of anti-spike antibodies on ACE2 binding</div>
<div class='caption-title'>Specificities of the antibodies used in this study, related to Figures 1 and ​and33</div>
Liu Y, Soh WT, Kishikawa JI, Hirose M, Nakayama EE, Li S, Sasai M, Suzuki T, Tada A, Arakawa A, Matsuoka S, Akamatsu K, Matsuda M, Ono C, Torii S, Kishida K, Jin H, Nakai W, Arase N, Nakagawa A, Matsumoto M, Nakazaki Y, Shindo Y, Kohyama M, Tomii K, Ohmura K, Ohshima S, Okamoto T, Yamamoto M, Nakagami H, Matsuura Y, Nakagawa A, Kato T, Okada M, Standley DM, Shioda T, Arase H
OpenAccess logo Cell 184 3452-3466.e18 (2021)
Related entries: 7dzw, 7dzy

Cited: 144 times
EuropePMC logo PMID: 34139176

Abstract

Antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein prevent SARS-CoV-2 infection. However, the effects of antibodies against other spike protein domains are largely unknown. Here, we screened a series of anti-spike monoclonal antibodies from coronavirus disease 2019 (COVID-19) patients and found that some of antibodies against the N-terminal domain (NTD) induced the open conformation of RBD and thus enhanced the binding capacity of the spike protein to ACE2 and infectivity of SARS-CoV-2. Mutational analysis revealed that all of the infectivity-enhancing antibodies recognized a specific site on the NTD. Structural analysis demonstrated that all infectivity-enhancing antibodies bound to NTD in a similar manner. The antibodies against this infectivity-enhancing site were detected at high levels in severe patients. Moreover, we identified antibodies against the infectivity-enhancing site in uninfected donors, albeit at a lower frequency. These findings demonstrate that not only neutralizing antibodies but also enhancing antibodies are produced during SARS-CoV-2 infection.

Reviews - 7dzx mentioned but not cited (1)

  1. Advances in antibody discovery from human BCR repertoires. Xu Z, Ismanto HS, Zhou H, Saputri DS, Sugihara F, Standley DM. Front Bioinform 2 1044975 (2022)

Articles - 7dzx mentioned but not cited (6)

  1. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Liu Y, Soh WT, Kishikawa JI, Hirose M, Nakayama EE, Li S, Sasai M, Suzuki T, Tada A, Arakawa A, Matsuoka S, Akamatsu K, Matsuda M, Ono C, Torii S, Kishida K, Jin H, Nakai W, Arase N, Nakagawa A, Matsumoto M, Nakazaki Y, Shindo Y, Kohyama M, Tomii K, Ohmura K, Ohshima S, Okamoto T, Yamamoto M, Nakagami H, Matsuura Y, Nakagawa A, Kato T, Okada M, Standley DM, Shioda T, Arase H. Cell 184 3452-3466.e18 (2021)
  2. Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. Mehra R, Kepp KP. ACS Infect Dis 8 29-58 (2022)
  3. Evaluation of immune evasion in SARS-CoV-2 Delta and Omicron variants. Chaudhari AM, Joshi M, Kumar D, Patel A, Lokhande KB, Krishnan A, Hanack K, Filipek S, Liepmann D, Renugopalakrishnan V, Paulmurugan R, Joshi C. Comput Struct Biotechnol J 20 4501-4516 (2022)
  4. Phylodynamic analysis and spike protein mutations in porcine deltacoronavirus with a new variant introduction in Taiwan. Hsueh FC, Wu CN, Lin MY, Hsu FY, Lin CF, Chang HW, Lin JH, Liu HF, Chiou MT, Chan KR, Lin CN. Virus Evol 7 veab096 (2021)
  5. Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants. Chi X, Xia L, Zhang G, Chi X, Huang B, Zhang Y, Chen Z, Han J, Wu L, Li Z, Sun H, Huang P, Yu C, Chen W, Zhou Q. Cell Discov 9 37 (2023)
  6. Structural and pKa Estimation of the Amphipathic HR1 in SARS-CoV-2: Insights from Constant pH MD, Linear vs. Nonlinear Normal Mode Analysis. Yánez Arcos DL, Thirumuruganandham SP. Int J Mol Sci 24 16190 (2023)


Reviews citing this publication (39)

  1. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, Liang KH, Hsieh TY, Wu HC. J Biomed Sci 29 1 (2022)
  2. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Goldblatt D, Alter G, Crotty S, Plotkin SA. Immunol Rev 310 6-26 (2022)
  3. The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. Rajah MM, Bernier A, Buchrieser J, Schwartz O. J Mol Biol 434 167280 (2022)
  4. Neutralizing antibodies for the prevention and treatment of COVID-19. Du L, Yang Y, Zhang X. Cell Mol Immunol 18 2293-2306 (2021)
  5. Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome? Theoharides TC. Mol Neurobiol 59 1850-1861 (2022)
  6. Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. Gartlan C, Tipton T, Salguero FJ, Sattentau Q, Gorringe A, Carroll MW. Front Immunol 13 882972 (2022)
  7. Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. Zhang Z, Shen Q, Chang H. Front Immunol 13 843928 (2022)
  8. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. BioDrugs 36 231-323 (2022)
  9. Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. Cheng ZJ, Xue M, Zheng P, Lyu J, Zhan Z, Hu H, Zhang Y, Zhang XD, Sun B. Vaccines (Basel) 9 869 (2021)
  10. "Is Omicron mild"? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies. Rajpal VR, Sharma S, Kumar A, Chand S, Joshi L, Chandra A, Babbar S, Goel S, Raina SN, Shiran B. J Med Virol 94 3521-3539 (2022)
  11. Role of the humoral immune response during COVID-19: guilty or not guilty? Yaugel-Novoa M, Bourlet T, Paul S. Mucosal Immunol 15 1170-1180 (2022)
  12. Antibody-Dependent Enhancement: ″Evil″ Antibodies Favorable for Viral Infections. Yang X, Zhang X, Zhao X, Yuan M, Zhang K, Dai J, Guan X, Qiu HJ, Li Y. Viruses 14 1739 (2022)
  13. Antibody-mediated immunity to SARS-CoV-2 spike. Errico JM, Adams LJ, Fremont DH. Adv Immunol 154 1-69 (2022)
  14. Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. Beeraka NM, Sukocheva OA, Lukina E, Liu J, Fan R. Rev Med Virol 32 e2346 (2022)
  15. Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel. Ng KW, Faulkner N, Wrobel AG, Gamblin SJ, Kassiotis G. Semin Immunol 55 101507 (2021)
  16. SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications. Yuan L, Tang Q, Zhu H, Guan Y, Cheng T, Xia N. Emerg Microbes Infect 10 1881-1889 (2021)
  17. COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. Wang S, Li L, Yan F, Gao Y, Yang S, Xia X. Vaccines (Basel) 9 1082 (2021)
  18. Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses. Li X, Zhang L, Chen S, Ouyang H, Ren L. Microorganisms 9 1479 (2021)
  19. Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. Liu M, Gan H, Liang Z, Liu L, Liu Q, Mai Y, Chen H, Lei B, Yu S, Chen H, Zheng P, Sun B. Front Microbiol 14 1122868 (2023)
  20. Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets. Hachim A, Kavian N, Valkenburg SA. Curr Opin Virol 50 139-146 (2021)
  21. Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies. Gattinger P, Ohradanova-Repic A, Valenta R. Int J Mol Sci 24 5352 (2023)
  22. Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin. Otsubo R, Yasui T. Pharmacol Ther 240 108233 (2022)
  23. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Abebe EC, Dejenie TA. Front Immunol 14 1055457 (2023)
  24. SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. Duerr R, Crosse KM, Valero-Jimenez AM, Dittmann M. Microorganisms 9 1389 (2021)
  25. SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo. Nakayama EE, Shioda T. Microorganisms 11 1015 (2023)
  26. The Elusive Coreceptors for the SARS-CoV-2 Spike Protein. Berkowitz RL, Ostrov DA. Viruses 15 67 (2022)
  27. The atomic portrait of SARS-CoV-2 as captured by cryo-electron microscopy. Fertig TE, Chitoiu L, Terinte-Balcan G, Peteu VE, Marta D, Gherghiceanu M. J Cell Mol Med 26 25-34 (2022)
  28. Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development. Karrow NA, Shandilya UK, Pelech S, Wagter-Lesperance L, McLeod D, Bridle B, Mallard BA. Vaccines (Basel) 9 1351 (2021)
  29. Neutralizing and enhancing antibodies against SARS-CoV-2. Liu Y, Arase H. Inflamm Regen 42 58 (2022)
  30. The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion? Wang Z, Zhou M, Fu Z, Zhao L. Front Immunol 12 693579 (2021)
  31. Ofeleein i mi Vlaptin-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. Kountouras J, Gialamprinou D, Kotronis G, Papaefthymiou A, Economidou E, Soteriades ES, Vardaka E, Chatzopoulos D, Tzitiridou-Chatzopoulou M, Papazoglou DD, Doulberis M. Medicina (Kaunas) 58 309 (2022)
  32. Evolving understanding of antibody-dependent enhancement (ADE) of SARS-CoV-2. Yang Y, Xu F. Front Immunol 13 1008285 (2022)
  33. The lymphatic system and COVID-19 vaccines. Miyasaka M. Front Immunol 13 1041025 (2022)
  34. Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection. Arriaga-Canon C, Contreras-Espinosa L, Rebollar-Vega R, Montiel-Manríquez R, Cedro-Tanda A, García-Gordillo JA, Álvarez-Gómez RM, Jiménez-Trejo F, Castro-Hernández C, Herrera LA. Int J Mol Sci 23 11058 (2022)
  35. Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review. Garg N, Kunamneni AS, Garg P, Sharma S, Sharma D, Kunamneni A. Can J Infect Dis Med Microbiol 2023 6695533 (2023)
  36. Contemporaneous SARS-CoV-2-Neutralizing Antibodies Mediated by N-glycan Shields. Baghaie L, Leroy F, Sheikhi M, Jafarzadeh A, Szewczuk MR, Sheikhi A. Viruses 15 2079 (2023)
  37. Recent Dengue Infection in Bangladesh: A Seasonal Endemic Progressing to Year-long Serious Health Concern. Akbar SMF, Khan S, Mahtab M, Mahtab MA, Yahiro T, Arafat SM, Sarker MAS, Podder PK, Hossain MS, Khandokar FA, Hassan MR, Rahim MA, Ashraf MA, Rony RS, Nishizono A. Euroasian J Hepatogastroenterol 13 145-151 (2023)
  38. Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19. Liu Z, Han Z, Jin X, An J, Kim J, Chen W, Kim JS, Zheng J, Deng J. Acta Pharm Sin B (2023)
  39. mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review. Boretti A. Clin Exp Med 24 23 (2024)

Articles citing this publication (98)

  1. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A, Nutalai R, Wang B, Dijokaite A, Khan S, Avinoam O, Bahar M, Skelly D, Adele S, Johnson SA, Amini A, Ritter TG, Mason C, Dold C, Pan D, Assadi S, Bellass A, Omo-Dare N, Koeckerling D, Flaxman A, Jenkin D, Aley PK, Voysey M, Costa Clemens SA, Naveca FG, Nascimento V, Nascimento F, Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Baillie V, Serafin N, Kwatra G, Da Silva K, Madhi SA, Nunes MC, Malik T, Openshaw PJM, Baillie JK, Semple MG, Townsend AR, Huang KA, Tan TK, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Constantinides B, Webster H, Crook D, Pollard AJ, Lambe T, OPTIC Consortium, ISARIC4C Consortium, Paterson NG, Williams MA, Hall DR, Fry EE, Mongkolsapaya J, Ren J, Schreiber G, Stuart DI, Screaton GR. Cell 185 467-484.e15 (2022)
  2. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Li D, Edwards RJ, Manne K, Martinez DR, Schäfer A, Alam SM, Wiehe K, Lu X, Parks R, Sutherland LL, Oguin TH, McDanal C, Perez LG, Mansouri K, Gobeil SMC, Janowska K, Stalls V, Kopp M, Cai F, Lee E, Foulger A, Hernandez GE, Sanzone A, Tilahun K, Jiang C, Tse LV, Bock KW, Minai M, Nagata BM, Cronin K, Gee-Lai V, Deyton M, Barr M, Von Holle T, Macintyre AN, Stover E, Feldman J, Hauser BM, Caradonna TM, Scobey TD, Rountree W, Wang Y, Moody MA, Cain DW, DeMarco CT, Denny TN, Woods CW, Petzold EW, Schmidt AG, Teng IT, Zhou T, Kwong PD, Mascola JR, Graham BS, Moore IN, Seder R, Andersen H, Lewis MG, Montefiori DC, Sempowski GD, Baric RS, Acharya P, Haynes BF, Saunders KO. Cell 184 4203-4219.e32 (2021)
  3. The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. Kimura I, Kosugi Y, Wu J, Zahradnik J, Yamasoba D, Butlertanaka EP, Tanaka YL, Uriu K, Liu Y, Morizako N, Shirakawa K, Kazuma Y, Nomura R, Horisawa Y, Tokunaga K, Ueno T, Takaori-Kondo A, Schreiber G, Arase H, Genotype to Phenotype Japan (G2P-Japan) Consortium, Motozono C, Saito A, Nakagawa S, Sato K. Cell Rep 38 110218 (2022)
  4. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cao Y, Song W, Wang L, Liu P, Yue C, Jian F, Yu Y, Yisimayi A, Wang P, Wang Y, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Meng B, Gupta RK, Jin R, Wang Y, Xie XS, Wang X. Cell Host Microbe 30 1527-1539.e5 (2022)
  5. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Beaudoin-Bussières G, Chen Y, Ullah I, Prévost J, Tolbert WD, Symmes K, Ding S, Benlarbi M, Gong SY, Tauzin A, Gasser R, Chatterjee D, Vézina D, Goyette G, Richard J, Zhou F, Stamatatos L, McGuire AT, Charest H, Roger M, Pozharski E, Kumar P, Mothes W, Uchil PD, Pazgier M, Finzi A. Cell Rep 38 110368 (2022)
  6. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Wang Z, Muecksch F, Cho A, Gaebler C, Hoffmann HH, Ramos V, Zong S, Cipolla M, Johnson B, Schmidt F, DaSilva J, Bednarski E, Ben Tanfous T, Raspe R, Yao K, Lee YE, Chen T, Turroja M, Milard KG, Dizon J, Kaczynska A, Gazumyan A, Oliveira TY, Rice CM, Caskey M, Bieniasz PD, Hatziioannou T, Barnes CO, Nussenzweig MC. Immunity 55 998-1012.e8 (2022)
  7. Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages. Maemura T, Kuroda M, Armbrust T, Yamayoshi S, Halfmann PJ, Kawaoka Y. mBio 12 e0198721 (2021)
  8. The puzzling mutational landscape of the SARS-2-variant Omicron. Fantini J, Yahi N, Colson P, Chahinian H, La Scola B, Raoult D. J Med Virol 94 2019-2025 (2022)
  9. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection. Okuya K, Hattori T, Saito T, Takadate Y, Sasaki M, Furuyama W, Marzi A, Ohiro Y, Konno S, Hattori T, Takada A. Microbiol Spectr 10 e0155321 (2022)
  10. Rapid characterization of spike variants via mammalian cell surface display. Javanmardi K, Chou CW, Terrace CI, Annapareddy A, Kaoud TS, Guo Q, Lutgens J, Zorkic H, Horton AP, Gardner EC, Nguyen G, Boutz DR, Goike J, Voss WN, Kuo HC, Dalby KN, Gollihar JD, Finkelstein IJ. Mol Cell 81 5099-5111.e8 (2021)
  11. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. Chen Y, Sun L, Ullah I, Beaudoin-Bussières G, Anand SP, Hederman AP, Tolbert WD, Sherburn R, Nguyen DN, Marchitto L, Ding S, Wu D, Luo Y, Gottumukkala S, Moran S, Kumar P, Piszczek G, Mothes W, Ackerman ME, Finzi A, Uchil PD, Gonzalez FJ, Pazgier M. Sci Adv 8 eabn4188 (2022)
  12. The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein. Resende PC, Naveca FG, Lins RD, Dezordi FZ, Ferraz MVF, Moreira EG, Coêlho DF, Motta FC, Paixão ACD, Appolinario L, Lopes RS, Mendonça ACDF, da Rocha ASB, Nascimento V, Souza V, Silva G, Nascimento F, Neto LGL, da Silva FV, Riediger I, Debur MDC, Leite AB, Mattos T, da Costa CF, Pereira FM, Dos Santos CA, Rovaris DB, Fernandes SB, Abbud A, Sacchi C, Khouri R, Bernardes AFL, Delatorre E, Gräf T, Siqueira MM, Bello G, Wallau GL. Virus Evol 7 veab069 (2021)
  13. Letter Adverse effects of COVID-19 vaccines and measures to prevent them. Yamamoto K. Virol J 19 100 (2022)
  14. Antibody dependent enhancement: Unavoidable problems in vaccine development. Xu L, Ma Z, Li Y, Pang Z, Xiao S. Adv Immunol 151 99-133 (2021)
  15. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. Zhao H, Wang TC, Li XF, Zhang NN, Li L, Zhou C, Deng YQ, Cao TS, Yang G, Li RT, Huang YJ, Li YG, Zhang YM, Li FX, Zhou YR, Jiang YH, Lu XS, Sun SH, Cheng ML, Gu KP, Zhang M, Ma QQ, Yang X, Ying B, Gao YW, Qin CF. Signal Transduct Target Ther 6 438 (2021)
  16. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Cheng SM, Mok CKP, Chan KC, Ng SS, Lam BH, Luk LL, Ko FW, Chen C, Yiu K, Li JK, Chan KK, Tsang LC, Poon LL, Hui DS, Peiris M. Euro Surveill 27 (2022)
  17. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Marconato M, Abela IA, Hauser A, Schwarzmüller M, Katzensteiner R, Braun DL, Epp S, Audigé A, Weber J, Rusert P, Schindler E, Pasin C, West E, Böni J, Kufner V, Huber M, Zaheri M, Schmutz S, Frey BM, Kouyos RD, Günthard HF, Manz MG, Trkola A. J Clin Invest 132 e158190 (2022)
  18. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. Zhou R, Wang P, Wong YC, Xu H, Lau SY, Liu L, Mok BW, Peng Q, Liu N, Woo KF, Deng S, Tam RC, Huang H, Zhang AJ, Zhou D, Zhou B, Chan CY, Du Z, Yang D, Au KK, Yuen KY, Chen H, Chen Z. EBioMedicine 75 103762 (2022)
  19. A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates. Yang L, Tian D, Han JB, Fan W, Zhang Y, Li Y, Sun W, Wei Y, Tian X, Yu DD, Feng XL, Cheng G, Bi Y, Zheng YT, Liu W. Innovation (Camb) 2 100140 (2021)
  20. ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection. Wang Z, Deng T, Zhang Y, Niu W, Nie Q, Yang S, Liu P, Pei P, Chen L, Li H, Cao B. iScience 25 103720 (2022)
  21. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. McNaughton AL, Paton RS, Edmans M, Youngs J, Wellens J, Phalora P, Fyfe A, Belij-Rammerstorfer S, Bolton JS, Ball J, Carnell GW, Dejnirattisai W, Dold C, Eyre DW, Hopkins P, Howarth A, Kooblall K, Klim H, Leaver S, Lee LN, López-Camacho C, Lumley SF, Macallan DC, Mentzer AJ, Provine NM, Ratcliff J, Slon-Compos J, Skelly D, Stolle L, Supasa P, Temperton N, Walker C, Wang B, Wyncoll D, Oxford Protective T Cell Immunology for COVID-19 (OPTIC) consortium, Scottish National Blood Transfusion Service (SNBTS) consortium, Simmonds P, Lambe T, Baillie JK, Semple MG, Openshaw PJ, International Severe Acute Respiratory and emerging Infection Consortium Coronavirus Clinical Characterisation Consortium (ISARIC4C) investigators, Obolski U, Turner M, Carroll M, Mongkolsapaya J, Screaton G, Kennedy SH, Jarvis L, Barnes E, Dunachie S, Lourenço J, Matthews PC, Bicanic T, Klenerman P, Gupta S, Thompson CP. JCI Insight 7 e156372 (2022)
  22. SARS-CoV-2 spike E156G/Δ157-158 mutations contribute to increased infectivity and immune escape. Mishra T, Dalavi R, Joshi G, Kumar A, Pandey P, Shukla S, Mishra RK, Chande A. Life Sci Alliance 5 e202201415 (2022)
  23. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity. Meng B, Datir R, Choi J, CITIID-NIHR Bioresource COVID-19 Collaboration, Bradley JR, Smith KGC, Lee JH, Gupta RK. Cell Rep 40 111220 (2022)
  24. Millisecond dynamic of SARS-CoV-2 spike and its interaction with ACE2 receptor and small extracellular vesicles. Lim K, Nishide G, Yoshida T, Watanabe-Nakayama T, Kobayashi A, Hazawa M, Hanayama R, Ando T, Wong RW. J Extracell Vesicles 10 e12170 (2021)
  25. SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. Hachim A, Gu H, Kavian O, Mori M, Kwan MYW, Chan WH, Yau YS, Chiu SS, Tsang OTY, Hui DSC, Mok CKP, Ma FNL, Lau EHY, Amarasinghe GK, Qavi AJ, Cheng SMS, Poon LLM, Peiris JSM, Valkenburg SA, Kavian N. Nat Commun 13 2951 (2022)
  26. A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. Cai X, Chen M, Prominski A, Lin Y, Ankenbruck N, Rosenberg J, Nguyen M, Shi J, Tomatsidou A, Randall G, Missiakas D, Fung J, Chang EB, Penaloza-MacMaster P, Tian B, Huang J. Adv Sci (Weinh) 9 e2103240 (2022)
  27. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. Coria LM, Saposnik LM, Pueblas Castro C, Castro EF, Bruno LA, Stone WB, Pérez PS, Darriba ML, Chemes LB, Alcain J, Mazzitelli I, Varese A, Salvatori M, Auguste AJ, Álvarez DE, Pasquevich KA, Cassataro J. Front Immunol 13 844837 (2022)
  28. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Fujigaki H, Yamamoto Y, Koseki T, Banno S, Ando T, Ito H, Fujita T, Naruse H, Hata T, Moriyama S, Takahashi Y, Suzuki T, Murakami T, Yoshida Y, Yagura Y, Oyamada T, Takemura M, Kondo M, Iwata M, Saito K. Microbiol Spectr 10 e0118121 (2022)
  29. CTD of SARS-CoV-2 N protein is a cryptic domain for binding ATP and nucleic acid that interplay in modulating phase separation. Dang M, Song J. Protein Sci 31 345-356 (2022)
  30. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Xu K, An Y, Li Q, Huang W, Han Y, Zheng T, Fang F, Liu H, Liu C, Gao P, Xu S, Liu X, Zhang R, Zhao X, Liu WJ, Bi Y, Wang Y, Zhou D, Wang Q, Hou W, Xia Q, Gao GF, Dai L. Emerg Microbes Infect 10 1574-1588 (2021)
  31. Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. Shimizu J, Sasaki T, Koketsu R, Morita R, Yoshimura Y, Murakami A, Saito Y, Kusunoki T, Samune Y, Nakayama EE, Miyazaki K, Shioda T. Sci Rep 12 15612 (2022)
  32. The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression. Pivniouk V, Pivniouk O, DeVries A, Uhrlaub JL, Michael A, Pivniouk D, VanLinden SR, Conway MY, Hahn S, Malone SP, Ezeh P, Churko JM, Anderson D, Kraft M, Nikolich-Zugich J, Vercelli D. J Allergy Clin Immunol 149 923-933.e6 (2022)
  33. Novel Neutralizing Epitope of PEDV S1 Protein Identified by IgM Monoclonal Antibody. Thavorasak T, Chulanetra M, Glab-Ampai K, Teeranitayatarn K, Songserm T, Yodsheewan R, Sae-Lim N, Lekcharoensuk P, Sookrung N, Chaicumpa W. Viruses 14 125 (2022)
  34. The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study. Zhou W, Tang B, Bai Y, Shao Y, Xiao Y, Tang S. Vaccine 40 7141-7150 (2022)
  35. Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia. Mauriello A, Scimeca M, Amelio I, Amelio I, Massoud R, Novelli A, Di Lorenzo F, Finocchiaro S, Cimino C, Telesca R, Chiocchi M, Sun Q, Sun Q, Wang Y, Shi Y, Novelli G, Melino G. Cell Death Dis 12 762 (2021)
  36. Dengue Infections during COVID-19 Period: Reflection of Reality or Elusive Data Due to Effect of Pandemic. Khan S, Akbar SMF, Yahiro T, Mahtab MA, Kimitsuki K, Hashimoto T, Nishizono A. Int J Environ Res Public Health 19 10768 (2022)
  37. Structural Dynamics of the SARS-CoV-2 Spike Protein: A 2-Year Retrospective Analysis of SARS-CoV-2 Variants (from Alpha to Omicron) Reveals an Early Divergence between Conserved and Variable Epitopes. Guérin P, Yahi N, Azzaz F, Chahinian H, Sabatier JM, Fantini J. Molecules 27 3851 (2022)
  38. The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production. Shimizu J, Sasaki T, Yamanaka A, Ichihara Y, Koketsu R, Samune Y, Cruz P, Sato K, Tanga N, Yoshimura Y, Murakami A, Yamada M, Itoi K, Nakayama EE, Miyazaki K, Shioda T. Sci Rep 11 23713 (2021)
  39. Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. Minenkova O, Santapaola D, Milazzo FM, Anastasi AM, Battistuzzi G, Chiapparino C, Rosi A, Gritti G, Borleri G, Rambaldi A, Dental C, Viollet C, Pagano B, Salvini L, Marra E, Luberto L, Rossi A, Riccio A, Merlo Pich E, Santoro MG, De Santis R. Mol Ther 30 1979-1993 (2022)
  40. Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. Zhu T, Xiao Y, Meng X, Tang L, Li B, Zhao Z, Tan Q, Shan H, Liu L, Huang X. J Nanobiotechnology 19 391 (2021)
  41. Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population. Yin Q, Zhang Y, Lian L, Qu Y, Wu W, Chen Z, Pei R, Chen T, Sun L, Li C, Li A, Li J, Li D, Wang S, Guan W, Liang M. Viruses 13 1508 (2021)
  42. Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2. Koyama T, Miyakawa K, Tokumasu R, S Jeremiah S, Kudo M, Ryo A. Future Microbiol 17 417-424 (2022)
  43. Pathogen evolution during vaccination campaigns. Day T, Kennedy DA, Read AF, Gandon S. PLoS Biol 20 e3001804 (2022)
  44. Time course of peripheral immunophenotypes of multisystem inflammatory syndrome in children. Morita A, Hosaka S, Imagawa K, Ishiodori T, Nozaki Y, Murakami T, Takada H. Clin Immunol 236 108955 (2022)
  45. Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis. Gan L, Chen Y, Tan J, Wang X, Zhang D. BMC Infect Dis 22 742 (2022)
  46. Long Term Immune Response Produced by the SputnikV Vaccine. Martynova E, Hamza S, Garanina EE, Kabwe E, Markelova M, Shakirova V, Khaertynova IM, Kaushal N, Baranwal M, Rizvanov AA, Urbanowicz RA, Khaiboullina SF. Int J Mol Sci 22 11211 (2021)
  47. Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity. Wu F, Luo S, Zhang Y, Ou Y, Wang H, Guo Z, He C, Bai S, He P, Jiang M, Chen X, Du G, Sun X. Acta Pharm Sin B 13 2219-2233 (2023)
  48. Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. Willcox AC, Sung K, Garrett ME, Galloway JG, Erasmus JH, Logue JK, Hawman DW, Chu HY, Hasenkrug KJ, Fuller DH, Matsen Iv FA, Overbaugh J. PLoS Pathog 18 e1010155 (2022)
  49. Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection. Mu S, Song S, Hao Y, Luo F, Wu R, Wang Y, Han X, Li T, Hu C, Li S, Shen M, Huang J, Wang W, Wang Y, Jin A. Front Med (Lausanne) 9 952697 (2022)
  50. A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. Gao F, Huang J, Li T, Hu C, Shen M, Mu S, Luo F, Song S, Hao Y, Wang W, Han X, Qian C, Wang Y, Wu R, Li L, Li S, Jin A. Front Immunol 12 789905 (2021)
  51. Co-existence of a pandemic (SARS-CoV-2) and an epidemic (Dengue virus) at some focal points in Southeast Asia: Pathogenic importance, preparedness, and strategy of tackling. Khan S, Akbar SMF, Nishizono A. Lancet Reg Health Southeast Asia 4 100046 (2022)
  52. Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection. Wieczorek L, Zemil M, Merbah M, Dussupt V, Kavusak E, Molnar S, Heller J, Beckman B, Wollen-Roberts S, Peachman KK, Darden JM, Krebs S, Rolland M, Peel SA, Polonis VR. Front Immunol 13 901217 (2022)
  53. Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases. Deakin CT, Cornish GH, Ng KW, Faulkner N, Bolland W, Hope J, Rosa A, Harvey R, Hussain S, Earl C, Jebson BR, Wilkinson MGLL, Marshall LR, O'Brien K, Rosser EC, Radziszewska A, Peckham H, Patel H, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Spyer MJ, Gamblin SJ, McCauley J, Nastouli E, Levin M, Cherepanov P, Ciurtin C, Wedderburn LR, Kassiotis G. Med 2 1093-1109.e6 (2021)
  54. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters. Shiwa-Sudo N, Sakai Y, Iwata-Yoshikawa N, Watanabe S, Yamada S, Kuroda Y, Yamamoto T, Shirakura M, Fujisaki S, Miyazaki K, Miura H, Nagata S, Fukushi S, Maeda K, Hasegawa H, Suzuki T, Nagata N. J Virol 97 e0136622 (2023)
  55. Landscape of infection enhancing antibodies in COVID-19 and healthy donors. Ismanto HS, Xu Z, Saputri DS, Wilamowski J, Li S, Nugraha DK, Horiguchi Y, Okada M, Arase H, Standley DM. Comput Struct Biotechnol J 20 6033-6040 (2022)
  56. Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. Roessler J, Pich D, Albanese M, Wratil PR, Krähling V, Hellmuth JC, Scherer C, von Bergwelt-Baildon M, Becker S, Keppler OT, Brisson A, Zeidler R, Hammerschmidt W. PNAS Nexus 1 pgac045 (2022)
  57. Targeting Emerging RNA Viruses by Engineered Human Superantibody to Hepatitis C Virus RNA-Dependent RNA Polymerase. Glab-Ampai K, Kaewchim K, Thavorasak T, Saenlom T, Thepsawat W, Mahasongkram K, Thueng-In K, Sookrung N, Chaicumpa W, Chulanetra M. Front Microbiol 13 926929 (2022)
  58. Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro. Luan N, Li T, Wang Y, Cao H, Yin X, Lin K, Liu C. Front Immunol 13 882856 (2022)
  59. Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein. Otsubo R, Minamitani T, Kobiyama K, Fujita J, Ito T, Ueno S, Anzai I, Tanino H, Aoyama H, Matsuura Y, Namba K, Imadome KI, Ishii KJ, Tsumoto K, Kamitani W, Yasui T. Sci Rep 12 20120 (2022)
  60. In Silico Discovery of Small Molecule Modulators Targeting the Achilles' Heel of SARS-CoV-2 Spike Protein. Wang Q, Meng F, Xie Y, Wang W, Meng Y, Li L, Liu T, Qi J, Ni X, Zheng S, Huang J, Huang N. ACS Cent Sci 9 252-265 (2023)
  61. Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19-convalescent individuals. Li M, Liu J, Lu R, Zhang Y, Du M, Xing M, Wu Z, Kong X, Zhu Y, Zhou X, Hu L, Zhang C, Zhou D, Jin X. J Allergy Clin Immunol 149 1225-1241 (2022)
  62. Nanoscopic Assessment of Anti-SARS-CoV-2 Spike Neutralizing Antibody Using High-Speed AFM. Lim K, Nishide G, Sajidah ES, Yamano T, Qiu Y, Yoshida T, Kobayashi A, Hazawa M, Ando T, Hanayama R, Wong RW. Nano Lett 23 619-628 (2023)
  63. SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters1. Zhou B, Zhou R, Chan JF, Zeng J, Zhang Q, Yuan S, Liu L, Robinot R, Shan S, Liu N, Ge J, Kwong HY, Zhou D, Xu H, Chan CC, Poon VK, Chu H, Yue M, Kwan KY, Chan CY, Chan CC, Chik KK, Du Z, Au KK, Huang H, Man HO, Cao J, Li C, Wang Z, Zhou J, Song Y, Yeung ML, To KK, Ho DD, Chakrabarti LA, Wang X, Zhang L, Yuen KY, Chen Z. Emerg Microbes Infect 12 2245921 (2023)
  64. SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity. Ait-Belkacem I, Cartagena García C, Millet-Wallisky E, Izquierdo N, Loosveld M, Arnoux I, Morange PE, Galland F, Lambert N, Malergue F, Busnel JM. Sci Rep 12 20824 (2022)
  65. CVID-Associated B Cell Activating Factor Receptor Variants Change Receptor Oligomerization, Ligand Binding, and Signaling Responses. Block V, Sevdali E, Recher M, Abolhassani H, Hammarstrom L, Smulski CR, Baronio M, Plebani A, Proietti M, Speletas M, Warnatz K, Voll RE, Lougaris V, Schneider P, Eibel H. J Clin Immunol 43 391-405 (2023)
  66. Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study. Yamashita K, Suzuki A, Takebayashi S, Toguchi A, Ogitani K, Niizeki N, Nagura O, Furuhashi K, Iwaizumi M, Maekawa M. Vaccines (Basel) 10 1050 (2022)
  67. Emerging SARS-CoV-2 variants follow a historical pattern recorded in outgroups infecting non-human hosts. Katoh K, Standley DM. Commun Biol 4 1134 (2021)
  68. Enhancing epitope of PEDV spike protein. Thavorasak T, Chulanetra M, Glab-Ampai K, Mahasongkram K, Sae-Lim N, Teeranitayatarn K, Songserm T, Yodsheewan R, Nilubol D, Chaicumpa W, Sookrung N. Front Microbiol 13 933249 (2022)
  69. Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients. Kashiwagi K, Jimbo K, Suzuki M, Arai N, Kudo T, Shimizu T. Vaccines (Basel) 10 1618 (2022)
  70. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Kaewchim K, Glab-Ampai K, Mahasongkram K, Saenlom T, Thepsawat W, Chulanetra M, Choowongkomon K, Sookrung N, Chaicumpa W. Viruses 15 1252 (2023)
  71. A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. Brandys P, Montagutelli X, Merenkova I, Barut GT, Thiel V, Schork NJ, Trüeb B, Conquet L, Deng A, Antanasijevic A, Lee HK, Valière M, Sindhu A, Singh G, Herold J. Front Immunol 13 912898 (2022)
  72. Antibody Response to the SARS-CoV-2 Spike and Nucleocapsid Proteins in Patients with Different COVID-19 Clinical Profiles. Soares SR, da Silva Torres MK, Lima SS, de Sarges KML, Santos EFD, de Brito MTFM, da Silva ALS, de Meira Leite M, da Costa FP, Cantanhede MHD, da Silva R, de Oliveira Lameira Veríssimo A, Vallinoto IMVC, Feitosa RNM, Quaresma JAS, Chaves TDSS, Viana GMR, Falcão LFM, Santos EJMD, Vallinoto ACR, da Silva ANMR. Viruses 15 898 (2023)
  73. Blistering Papulosquamous Erythema with Arthralgia: A Quiz. Kurosaki Y, Ishitsuka Y, Kato Y, Arase N, Fujimoto M. Acta Derm Venereol 102 adv00690 (2022)
  74. COVID-19 vaccination in patients with α1-antitrypsin deficiency. Yang C, Zhao H. Lancet Respir Med 9 818-820 (2021)
  75. Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity. Kuzmina A, Korovin D, Cohen Lass I, Atari N, Ottolenghi A, Hu P, Mandelboim M, Rosental B, Rosenberg E, Diaz-Griffero F, Taube R. Heliyon 9 e16750 (2023)
  76. Dengue outbreaks in South Asia amid Covid-19: Epidemiology, transmission, and mitigation strategies. Manna S, Satapathy P, Bora I, Padhi BK. Front Public Health 10 1060043 (2022)
  77. Non-Neutralizing Epitopes Shade Neutralizing Epitopes against Omicron in a Multiple Epitope-Based Vaccine. Gong HR, Hu YF, Li X, Yau T, Zhang BZ, Huang JD. ACS Infect Dis 8 2586-2593 (2022)
  78. The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms. Cross RW, Wiethoff CM, Brown-Augsburger P, Berens S, Blackbourne J, Liu L, Wu X, Tetreault J, Dodd C, Sina R, Witcher DR, Newcomb D, Frost D, Wilcox A, Borisevich V, Agans KN, Woolsey C, Prasad AN, Deer DJ, Geisbert JB, Dobias NS, Fenton KA, Strifler B, Ebert P, Higgs R, Beall A, Chanda S, Riva L, Yin X, Geisbert TW. Pathogens 12 1408 (2023)
  79. Letter The immunodominance of RBD antigen of delta variant as vaccine candidate against SARS-CoV-2 infection. Luo D, Li T, Yang X, Ning N, Zhang L, Gu H, Li D, Yu W, Hu Z, Wang H. J Med Virol 95 e28359 (2023)
  80. α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants. Zou J, Jing H, Zhang X, Liu Y, Zhao Z, Duan L, Yuan Y, Chen Z, Gou Q, Xiong Q, Li S, Yang F, Zeng H, Zou Q, Zhang J. Front Immunol 12 757691 (2021)
  81. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern. Wu D, Cong J, Wei J, Hu J, Sun W, Ran W, Liao C, Zheng H, Ye L. Int J Nanomedicine 18 5781-5795 (2023)
  82. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants. Honda-Okubo Y, Bowen R, Barker M, Bielefeldt-Ohmann H, Petrovsky N. Vaccine 41 7116-7128 (2023)
  83. Anti-spike protein antibody responses to BNT162b2 mRNA vaccine: A single-center survey in a COVID-19 non-epidemic area in Japan. Mokuda S, Kawanishi N, Kuroshima S, Kono J, Nakayama H, Mieno H, Kawamoto M. Vaccine X 11 100173 (2022)
  84. Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: a retrospective cohort study with prospective follow-up. Triebelhorn J, Schneider J, Spinner CD, Iakoubov R, Voit F, Wagner L, Erber J, Rothe K, Berthele A, Pernpeintner V, Strauß EM, Renders L, Willmann A, Minic M, Vogel E, Christa C, Hoffmann D, Protzer U, Jeske SD. Infection (2024)
  85. Cross-Reactivity of Antibodies in Intravenous Immunoglobulin Preparation for Protection against SARS-CoV-2. Osaka T, Yamamoto Y, Soma T, Yanagisawa N, Nagata S. Microorganisms 11 471 (2023)
  86. Deciphering the antigen specificities of antibodies by clustering their complementarity determining region sequences. Saputri DS, Ismanto HS, Nugraha DK, Xu Z, Horiguchi Y, Sakakibara S, Standley DM. mSystems 8 e0072223 (2023)
  87. Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination. Yin D, Han Z, Lang B, Li Y, Mai G, Chen H, Feng L, Chen YQ, Luo H, Xiong Y, Jing L, Du X, Shu Y, Sun C. Front Immunol 14 1195533 (2023)
  88. Enhancement of SARS-CoV-2 Infection via Crosslinking of Adjacent Spike Proteins by N-Terminal Domain-Targeting Antibodies. Lusiany T, Terada T, Kishikawa JI, Hirose M, Chen DV, Sugihara F, Ismanto HS, van Eerden FJ, Li S, Kato T, Arase H, Yoshiharu M, Okada M, Standley DM. Viruses 15 2421 (2023)
  89. Longitudinal Analyses after COVID-19 Recovery or Prolonged Infection Reveal Unique Immunological Signatures after Repeated Vaccinations. Hisamatsu D, Ikeda A, Ito L, Matsushita Y, Hiki M, Mori H, Tabe Y, Naito T, Akazawa C. Vaccines (Basel) 10 1815 (2022)
  90. Mathematical modeling the dynamics of SARS-CoV-2 infection with antibody-dependent enhancement. Song H, Yuan Z, Liu S, Jin Z, Sun G. Nonlinear Dyn 111 2943-2958 (2023)
  91. Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients: lessons from early variant infection and impact on shaping emerging variants. Coutant F, Touret F, Pin JJ, Alonzo M, Baronti C, Munier S, Attia M, de Lamballerie X, Ferry T, Miossec P. Emerg Microbes Infect 13 2307510 (2024)
  92. Plasma Exchange in a Patient with Immune Thrombocytopenia Associated with Antiphospholipid Syndrome Hospitalized for COVID-19. Boggio F, Ciavarella A, Arcudi S, Gualtierotti R, Rossio R, Tafuri F, Artoni A, Peyvandi F. Rheumatol Ther 9 1213-1219 (2022)
  93. Presence of neutralizing SARS-CoV-2 antibodies in asymptomatic population of N'Djamena, Chad. Wondeu ALD, Abakar MF, Frasca F, Nodjikouambaye AZ, Abdelrazakh F, Naibei N, Dzomo GRT, Djimtoibaye D, Mad-Toingue J, Scagnolari C, Antonelli G, Linardos G, Russo C, Perno CF, Yandai FH, Atturo S, Hiscott J, Colizzi V, Cappelli G, Ngueadoum N, Haroun A, Choua O, Moussa AM. Immun Inflamm Dis 12 e1154 (2024)
  94. Prior COVID-19 Immunization Does Not Cause IgA- or IgG-Dependent Enhancement of SARS-CoV-2 Infection. Yaugel-Novoa M, Noailly B, Jospin F, Berger AE, Waeckel L, Botelho-Nevers E, Longet S, Bourlet T, Paul S. Vaccines (Basel) 11 773 (2023)
  95. Profiles of Cough and Associated Risk Factors in Nonhospitalized Individuals With SARS-CoV-2 Omicron Variant Infection: Cross-Sectional Online Survey in China. Xu T, Chen Y, Zhan W, Chung KF, Qiu Z, Huang K, Chen R, Xie J, Wang G, Zhang M, Wang X, Yao H, Liao X, Zhang Y, Zhang G, Zhang W, Sun D, Zhu J, Jiang S, Feng J, Zhao J, Sun G, Huang H, Zhang J, Wang L, Wu F, Li S, Xu P, Chi C, Chen P, Jiang M, He W, Huang L, Luo W, Li S, Zhong N, Lai K, China Cough Coalition. JMIR Public Health Surveill 10 e47453 (2024)
  96. Secondary structure assignment of proteins in the absence of sequence information. Khalife S, Malliavin T, Liberti L. Bioinform Adv 1 vbab038 (2021)
  97. Structural basis of anti-SARS-CoV-2 activity of HCQ: specific binding to N protein to disrupt its interaction with nucleic acids and LLPS. Dang M, Song J. QRB Discov 2 e13 (2021)
  98. The influence of single-point mutation D614G on the binding process between human angiotensin-converting enzyme 2 and the SARS-CoV-2 spike protein-an atomistic simulation study. Shi C, Jiao Y, Yang C, Sun Y. RSC Adv 13 9800-9810 (2023)


Quick links